|
1
|
Cho NH, Shaw JE, Karuranga S, Huang Y, da
Rocha Fernandes JD, Ohlrogge AW and Malanda B: IDF diabetes atlas:
Global estimates of diabetes prevalence for 2017 and projections
for 2045. Diabetes Res Clin Pract. 138:271–281. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lu Y, Li Y, Li G and Lu H: Identification
of potential markers for type 2 diabetes mellitus via
bioinformatics analysis. Mol Med Rep. 22:1868–1882. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ichise M and Harris PE: Imaging of
beta-cell mass and function. J Nucl Med. 51:1001–1004. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
DeFronzo RA, Eldor R and Abdul-Ghani M:
Pathophysiologic approach to therapy in patients with newly
diagnosed type 2 diabetes. Diabetes Care. 36 (Suppl 2):S127–S138.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weir GC and Bonner-Weir S: Islet β cell
mass in diabetes and how it relates to function, birth, and death.
Ann N Y Acad Sci. 1281:92–105. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Butler AE, Janson J, Bonner-Weir S, Ritzel
R, Rizza RA and Butler PC: Beta-cell deficit and increased
beta-cell apoptosis in humans with type 2 diabetes. Diabetes.
52:102–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Germonpre P, Levie P, Dehalleux C and
Caers D: ENT indications for Hyperbaric Oxygen Therapy. B-ENT
Suppl. 26:S87–S106. 2016.PubMed/NCBI
|
|
8
|
Karadurmus N, Sahin M, Tasci C, Naharci I,
Ozturk C, Ilbasmis S, Dulkadir Z, Sen A and Saglam K: Potential
benefits of hyperbaric oxygen therapy on atherosclerosis and
glycaemic control in patients with diabetic foot. Endokrynol Pol.
61:275–279. 2010.PubMed/NCBI
|
|
9
|
Chen CY, Wu RW, Hsu MC, Hsieh CJ and Chou
MC: Adjunctive hyperbaric oxygen therapy for healing of chronic
diabetic foot ulcers: A randomized controlled trial. J Wound Ostomy
Continence Nurs. 44:536–545. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wilkinson D, Nolting M, Mahadi MK, Chapman
I and Heilbronn L: Hyperbaric oxygen therapy increases insulin
sensitivity in overweight men with and without type 2 diabetes.
Diving Hyperb Med. 45:30–36. 2015.PubMed/NCBI
|
|
11
|
Wilkinson D, Chapman IM and Heilbronn LK:
Hyperbaric oxygen therapy improves peripheral insulin sensitivity
in humans. Diabet Med. 29:986–989. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagatomo F, Takemura A, Roy RR, Fujino H,
Kondo H and Ishihara A: Mild hyperbaric oxygen inhibits the
growth-related decline in skeletal muscle oxidative capacity and
prevents hyperglycemia in rats with type 2 diabetes mellitus. J
Diabetes. 10:753–763. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Y, Zhang D, Yuan J, Song L, Zhang C,
Lin Q, Li M, Sheng Z, Ma Z, Lv F, et al: Hyperbaric oxygen
ameliorates insulin sensitivity by increasing GLUT4 expression in
skeletal muscle and stimulating UCP1 in brown adipose tissue in
T2DM mice. Front Endocrinol (Lausanne). 11:322020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jansson L and Hellerström C: Stimulation
by glucose of the blood flow to the pancreatic islets of the rat.
Diabetologia. 25:45–50. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kleinert M, Clemmensen C, Hofmann SM,
Moore MC, Renner S, Woods SC, Huypens P, Beckers J, de Angelis MH,
Schürmann A, et al: Animal models of obesity and diabetes mellitus.
Nat Rev Endocrinol. 14:140–162. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu T, Sungelo MJ, Goldberg IJ, Wang H and
Eckel RH: Streptozotocin-treated high fat fed mice: A new type 2
diabetes model used to study canagliflozin-induced alterations in
lipids and lipoproteins. Horm Metab Res. 49:400–406. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan J, Jiang Q, Song L, Liu Y, Li M, Lin
Q, Li Y, Su K, Ma Z, Wang Y, et al: L-Carnitine is involved in
hyperbaric oxygen-mediated therapeutic effects in high fat
diet-induced lipid metabolism dysfunction. Molecules. 25:1762020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang D, Yu YJ, Xu FS, Yuan JH, Wang R,
Zhang CS, Wang LX, Liu Y, Song LM, Liu JL and Dong J: Recombinant
betatrophin (Angptl-8/lipasin) ameliorates streptozotocin-induced
hyperglycemia and β-cell destruction in neonatal rats. Mol Med Rep.
20:4523–4532. 2019.PubMed/NCBI
|
|
19
|
Song L, Yuan J, Liu Y, Zhang D, Zhang C,
Lin Q, Li M, Su K, Li Y, Gao G, et al: Ghrelin system is involved
in improvements in glucose metabolism mediated by hyperbaric oxygen
treatment in a streptozotocin-induced type 1 diabetes mouse model.
Mol Med Rep. 22:3767–3776. 2020.PubMed/NCBI
|
|
20
|
Jensen TL, Kiersgaard MK, Sørensen DB and
Mikkelsen LF: Fasting of mice: A review. Lab Anim. 47:225–240.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei X, Gu N, Feng N, Guo X and Ma X:
Inhibition of p38 mitogen-activated protein kinase exerts a
hypoglycemic effect by improving β cell function via inhibition of
β cell apoptosis in db/db mice. J Enzyme Inhib Med Chem.
33:1494–1500. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cui X, Wang B, Wu Y, Xie L, Xun P, Tang Q,
Cai W and Shen X: Vegetarians have a lower fasting insulin level
and higher insulin sensitivity than matched omnivores: A
cross-sectional study. Nutr Metab Cardiovasc Dis. 29:467–473. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kou K, Saisho Y, Satoh S, Yamada T and
Itoh H: Change in β-cell mass in Japanese nondiabetic obese
individuals. J Clin Endocrinol Metab. 98:3724–3730. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lautenbach A, Wernecke M, Riedel N, Veigel
J, Yamamura J, Keller S, Jung R, Busch P, Mann O, Knop FK, et al:
Adaptive changes in pancreas post Roux-en-Y gastric bypass induced
weight loss. Diabetes Metab Res Rev. 34:e30252018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Poret JM, Souza-Smith F, Marcell SJ,
Gaudet DA, Tzeng TH, Braymer HD, Harrison-Bernard LM and Primeaux
SD: High fat diet consumption differentially affects adipose tissue
inflammation and adipocyte size in obesity-prone and
obesity-resistant rats. Int J Obes (Lond). 42:535–541. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Siersbæk MS, Ditzel N, Hejbøl EK,
Præstholm SM, Markussen LK, Avolio F, Li L, Lehtonen L, Hansen AK,
Schrøder HD, et al: C57BL/6J substrain differences in response to
high-fat diet intervention. Sci Rep. 10:140522020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Faselis C, Katsimardou A, Imprialos K,
Deligkaris P, Kallistratos M and Dimitriadis K: Microvascular
complications of type 2 diabetes mellitus. Curr Vasc Pharmacol.
18:117–124. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stumvoll M and Gerich J: Clinical features
of insulin resistance and beta cell dysfunction and the
relationship to type 2 diabetes. Clin Lab Med. 21:31–51.
2001.PubMed/NCBI
|
|
29
|
Elosta A, Ghous T and Ahmed N: Natural
products as anti-glycation agents: possible therapeutic potential
for diabetic complications. Curr Diabetes Rev. 8:92–108. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo S: Insulin signaling, resistance, and
the metabolic syndrome: insights from mouse models into disease
mechanisms. J Endocrinol. 220:T1–T23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Utumatwishima JN, Chung ST, Bentley AR,
Udahogora M and Sumner AE: Reversing the tide-diagnosis and
prevention of T2DM in populations of African descent. Nat Rev
Endocrinol. 14:45–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
DeFronzo RA, Ferrannini E, Groop L, Henry
RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, et al:
Type 2 diabetes mellitus. Nat Rev Dis Primers. 1:150192015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kitamura T: The role of FOXO1 in β-cell
failure and type 2 diabetes mellitus. Nat Rev Endocrinol.
9:615–623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Freeman AM and Pennings N: Insulin
Resistance. StatPearls (Internet); Treasure Island, FL: 2021
https://www.ncbi.nlm.nih.gov/books/NBK507839July
10–2021
|
|
35
|
Hjermann I: The metabolic cardiovascular
syndrome: Syndrome X, Reaven's syndrome, insulin resistance
syndrome, atherothrombogenic syndrome. J Cardiovasc Pharmacol. 20
(Suppl 8):S5–S10. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stumvoll M and Häring H: Insulin
resistance and insulin sensitizers. Horm Res. 55 (Suppl 2):3–13.
2001.PubMed/NCBI
|
|
37
|
Klip A and Pâquet MR: Glucose transport
and glucose transporters in muscle and their metabolic regulation.
Diabetes Care. 13:228–243. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rui L: Energy metabolism in the liver.
Compr Physiol. 4:177–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Faleo G, Fotino C, Bocca N, Molano RD,
Zahr-Akrawi E, Molina J, Villate S, Umland O, Skyler JS, Bayer AL,
et al: Prevention of autoimmune diabetes and induction of β-cell
proliferation in NOD mice by hyperbaric oxygen therapy. Diabetes.
61:1769–1778. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Matsunami T, Sato Y, Hasegawa Y, Ariga S,
Kashimura H, Sato T and Yukawa M: Enhancement of reactive oxygen
species and induction of apoptosis in streptozotocin-induced
diabetic rats under hyperbaric oxygen exposure. Int J Clin Exp
Pathol. 4:255–266. 2011.PubMed/NCBI
|
